Elastase inhibitor prodrug and use thereof
By developing compounds with specific structures of Formula I, the problem of short exposure time of existing elastase inhibitors in vivo is solved, higher lung exposure and longer half-life are achieved, pharmacokinetic characteristics are improved, and pharmacokinetic properties are enhanced. The treatment effect on chronic obstructive pulmonary disease.
Patent Information
- Application Number
- CN202180018779.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-03-09
- Filing Date
- 2021-03-08
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-03-08
AI Technical Summary
Existing elastase inhibitors have short exposure time and are quickly eliminated, which limits their efficacy and cannot effectively treat chronic lung diseases caused by excessive elastase, such as chronic obstructive pulmonary disease.
A class of compounds with a specific structure of formula I or pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotope markers thereof have higher lung exposure and longer half-life, Residence time in the lungs by improving pharmacokinetic properties.
It significantly improves the concentration and residence time of active compounds in the lungs, improves pharmacokinetic characteristics, and enhances the therapeutic effect on diseases such as chronic obstructive pulmonary disease.
Smart Images

Figure CN115210244B_ABST
Abstract
Description
[0001] Citation of Related Applications
[0002] The present invention claims priority to invention patent application entitled “A prodrug of an elastase inhibitor and its use” and application number 202010155890.9 filed in China on March 9, 2020, and the entire contents of the patent application are incorporated herein by reference. Technical Field
[0003] The present invention belongs to the field of compounds, and specifically relates to a prodrug of a substituted boronic acid compound, and specifically relates to a mixture or composition of prodrugs of substituted boronic acid compounds, especially a mixture or composition of prodrugs of boronic acid compounds as elastase inhibitors, which is used to treat various lung diseases caused by excessive elastase, including chronic obstructive pulmonary disease (COPD). Background Art
[0004] Human neutrophil elastase (HNE) is a 32kDa serine protease. The pathological process of many diseases involves this protease. Excessive elastase is so destructive to the human body that the liver will specifically synthesize and secrete a natural inhibitor (α-1 antitrypsin) to maintain the balance of elastase activity in the human body. After being synthesized in neutrophils, elastase is stored in azurophilic granules until the neutrophils are activated by external signals and then secreted (Takahashi H., Nukiwa T., Basset P., Crystal RG, J. Biol. Chem., 1988, 263 (5): 2543-2547). Its main function is to degrade elastin. Elastin is one of the main components of extracellular matrix proteins, and other components include fibronectin, laminin, proteoglycans, type III and type IV collagen (Bieth JG, Elastases: catalytic and biological properties, in "Regulation of Matrix Accumulation", Mecham, RP (Eds), Academic Press, NY, USA, 1986, 217-306). The role of elastase includes resisting bacterial invasion by degrading bacterial structural proteins. In short, human elastase can degrade damaged tissues or invading bacteria, and plays an indispensable role in maintaining body homeostasis.
[0005] Alpha-1 antitrypsin deficiency (A1AD) is a genetic disease characterized by the lack of alpha-1 antitrypsin, a natural inhibitor of elastase, which causes excessive proteases to destroy the extracellular matrix of bronchiolar and alveolar epithelial cells due to imbalance (Laurell and Eriksson, Scand. J. Clin. Lab. Invest., 1963, 15: 132-140). Its pathological process strongly confirms the causal relationship between excessive elastase activity and chronic lung injury diseases, especially symptoms such as airflow limitation and emphysema. In another genetic disease, cystic fibrosis, inactivated CFTR protein leads to excessively viscous mucus and chronic inflammatory reactions in the trachea, which in turn produces excessive accumulation of elastase, which ultimately damages the lung tissue structure and limits its function.
[0006] In addition to the two genetic diseases mentioned above, elastase also plays a key role in several other chronic lung diseases, including pulmonary fibrosis, pneumonia, acute respiratory distress syndrome, chronic bronchiolitis, emphysema, etc. Among them, chronic lung diseases such as airflow limitation caused by long-term tracheal inflammation and dyspnea caused by emphysema are collectively referred to as chronic obstructive pulmonary disease (COPD).
[0007] COPD is a disease with a high incidence rate. There are about 100 million COPD patients in China, and this number is still increasing due to factors such as the aging population and air pollution. There is currently no effective treatment for this disease. The bronchodilators (LABA / LAMA) currently used can only relieve symptoms but cannot prevent the progression of the disease. These patients will continue to have lung infections, and the degree of lung function damage will worsen after each inflammation.
[0008] In summary, elastase inhibitors may be effective for the above diseases. Currently, several inhibitors have entered clinical trials or are in clinical trials to test the therapeutic effects on diseases such as chronic obstructive pulmonary disease, cystic fibrosis or alpha-1 antitrypsin deficiency. However, these clinical trials have either failed or have not yet produced results. Most of the reasons for failure are not poor activity, but because of toxicity (covalent binding to elastase), pharmacokinetics (no lung enrichment) and other reasons. WO 2018 / 175173 A1 mentions a boron-containing compound 52, whose structure is shown below.
[0009]
[0010] This compound is synthesized using innovative chemical methods and reversibly covalently binds to elastase. It is a new type of elastase inhibitor with excellent properties such as high lung enrichment rate. However, in vivo pharmacokinetic studies in animals have found that the compound has too short an exposure time in the lungs and is eliminated quickly, which may limit its efficacy. Therefore, it is necessary to develop a class of elastase inhibitors with longer in vivo exposure time and higher exposure. Summary of the invention
[0011] Problem that the invention aims to solve
[0012] In order to solve the above technical problems, the present invention provides a series of prodrug compounds having higher lung exposure and longer half-life compared with compound 52 in WO 2018 / 175173 A1.
[0013] Solutions for solving problems
[0014] In order to solve the above technical problems, the present invention provides the following technical solutions:
[0015] A compound having a structure of formula I or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope-labeled substance thereof:
[0016]
[0017] in,
[0018] When n is 0,
[0019] X and Y are directly connected, X and Y are CR 4 and CR 5 ;
[0020] R 4 and R 5 are each independently selected from hydrogen, deuterium and C 1-6 alkyl;
[0021] R 1 and R 2 are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl and C 3-8 Cycloalkyl, or, R 1 and R 2 connected to form unsubstituted or one or more R 6 Substituted C 3-8 Cycloalkyl;
[0022] If present, each R 6 are each independently selected from hydrogen, deuterium, hydroxyl, amino, halogen, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl and C1-6 Alkoxy;
[0023] Or, when n is an integer from 1 to 5,
[0024] XR 1 and YR 2 Each independently selected from carbonyl and CHR 7 ;
[0025] If present, each R 7 are each independently selected from hydrogen, deuterium and C 1-6 alkyl;
[0026] Each Z is independently selected from O, S, CH and N, and when Z is O or S, the R 3 does not exist;
[0027] If present, each R 3 are each independently selected from hydrogen, deuterium and C 1-6 alkyl.
[0028] The present invention also provides a pharmaceutical composition comprising any of the above compounds or pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotope-labeled substances thereof.
[0029] The present invention also provides the use of any of the above compounds or their pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotope labels, or the above pharmaceutical compositions, in the preparation of drugs for preventing and / or treating diseases at least partially mediated by elastase, preferably in the preparation of drugs for preventing and / or treating chronic obstructive pulmonary disease.
[0030] The present invention also provides any of the above-mentioned compounds or their pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotope labels, or the above-mentioned pharmaceutical compositions, which are used as drugs for preventing and / or treating diseases at least partially mediated by elastase, preferably as drugs for preventing and / or treating chronic obstructive pulmonary disease.
[0031] The present invention also provides a method for preventing and / or treating a disease at least partially mediated by elastase, comprising the following steps: administering a therapeutically effective amount of any of the above compounds or their pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotope labels, or the above pharmaceutical composition to a patient in need thereof.
[0032] Effects of the Invention
[0033] The compounds of the present invention have the advantages of high lung exposure and long half-life compared to compound 52 (control) in WO 2018 / 175173 A1. The prodrug compounds of the present invention greatly increase the concentration and residence time of the active compound (control) in the lungs, and have significant improvements in in vivo pharmacokinetics compared to the control. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 The stability data of the compound of Example 1 in simulated lung fluid at 37°C are shown;
[0035] Figure 2 The stability data of the compound of Example 2 in simulated lung fluid at 37°C are shown;
[0036] Figure 3 The stability data of the compound of Example 1 in different solvents at room temperature are shown;
[0037] Figure 4 The stability data of the compound of Example 2 in different solvents at room temperature are shown;
[0038] Figure 5 The lung drug concentrations after intratracheal administration of the control to mice (2 mg / kg) are shown;
[0039] Figure 6 The drug concentration of the compound of Example 1 and the drug concentration of the hydrolyzate as a control in the lungs after intratracheal administration (2 mg / kg) to mice are shown. DETAILED DESCRIPTION
[0040] In order to more clearly describe the content of the present invention, all terms involved in this application are defined as follows:
[0041] The term "C 1-6 The term “alkyl”, alone or in combination, means a saturated straight-chain or branched alkyl group containing 1 to 6, especially 1 to 4 carbon atoms, including methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, n-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3,-dimethyl-2-butyl, etc. In particular, “C 1-6 The "alkyl group" is any one of methyl, ethyl, isopropyl and tert-butyl.
[0042] The term "C 3-8"Cycloalkyl" alone or in combination means a saturated cycloalkyl group having 3 to 8, especially 5 to 7 carbon atoms, including monocyclic, bicyclic, bridged and spirocyclic rings. Specifically, the monocyclic ring includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like; the bicyclic ring includes bicyclo[2.2.0]hexyl, bicyclo[3.1.0]hexyl, bicyclo[3.2.0]heptyl, bicyclo[3.3.0]octyl, bicyclo[4.1.0 ]heptyl, bicyclo[4.2.0]octyl, etc.; the bridged ring includes bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, bicyclo[3.1.1]heptyl, bicyclo[3.2.1]octyl, bicyclo[4.1.1]octyl, etc.; the spiro ring includes spiro[2.2]pentyl, spiro[2.3]hexyl, spiro[3.3]heptyl, spiro[2.4]heptyl, spiro[3.4]octyl, spiro[2.5]octyl. In particular, "C 5-8 The "cycloalkyl" is any of bicyclo[2.2.2]octyl and bicyclo[3.1.1]heptyl.
[0043] The term "C 1-6 "Alkoxy" alone or in combination means a group C 1-6 Alkyl-O-, where "C 1-6 "Alkyl" is as defined above.
[0044] The term "amino" alone or in combination means a primary amino group (-NH2), a secondary amino group (-NH-) or a tertiary amino group.
[0045] The term "hydroxy", alone or in combination, denotes the group -OH.
[0046] The term "halogen" alone or in combination denotes fluorine, chlorine, bromine or iodine. In particular, "halogen" is fluorine, chlorine or bromine.
[0047] The term "isomer" includes all isomeric forms, including enantiomers, diastereomers and geometric isomers (including cis-trans isomers). Therefore, single stereochemical isomers of the compounds of the present invention or mixtures of their enantiomers, diastereomers, or geometric isomers (or cis-trans isomers) are all within the scope of the present invention.
[0048] The term "pharmaceutically acceptable salt" means that the compounds of the present invention exist in the form of their pharmaceutical salts, including acid addition salts and base addition salts. Pharmaceutically acceptable salts are described in pharmaceutically salts in SM Berge, J. Pharmaceutical Sciences, 1977, 66: 1-19. In the present invention, pharmaceutically acceptable non-toxic acid addition salts represent salts formed by the compounds of the present invention and organic or inorganic acids, and organic or inorganic acids include but are not limited to hydrochloric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, nitric acid, perchloric acid, acetic acid, oxalic acid, maleic acid, fumaric acid, tartaric acid, benzenesulfonic acid, methanesulfonic acid, salicylic acid, succinic acid, citric acid, lactic acid, propionic acid, benzoic acid, p-toluenesulfonic acid, malic acid, etc. Pharmaceutically acceptable non-toxic base addition salts refer to salts formed by compounds of the present invention with organic or inorganic bases, including but not limited to alkali metal salts, such as lithium, sodium or potassium salts; alkaline earth metal salts, such as calcium or magnesium salts; organic base salts, such as ammonium salts or N-containing organic bases. + (C 1-6 "Pharmaceutically acceptable salts" can be synthesized by common chemical methods.
[0049] The term "ester" refers to an ester formed by one or more hydroxyl groups in the compound of the present invention and any one or more protonic acids such as carboxylic acid, phosphoric acid, carbonic acid, sulfonic acid, boric acid, etc., or an ester formed by one or more carboxyl groups in the compound of the present invention and alcohol and / or phenol.
[0050] The term "solvate" refers to an association formed between one or more solvent molecules and the compounds of the present invention. Solvents that form solvates include, but are not limited to, water, methanol, ethanol, isopropanol, ethyl acetate, tetrahydrofuran, N,N-dimethylformamide, dimethyl sulfoxide, etc. In particular, "hydrate" refers to an association formed between water and the compounds of the present invention.
[0051] The term "prodrug" refers to a chemical derivative of the compound of the present invention, which is converted into the compound represented by the general formula I through a chemical reaction in vivo.
[0052] The term "isotopic derivative" refers to an isotopic derivative obtained by replacing a hydrogen atom in a compound of the present invention with 1 to 6 deuterium atoms and / or a carbon atom in a compound of the present invention with 1 to 3 deuterium atoms. 14 Isotopic derivatives obtained by replacing C atoms.
[0053] The terms involved in the present invention are defined above. Those skilled in the art can also understand the above terms in combination with the prior art. The following is a further description based on the content of the present invention and the definitions of the terms.
[0054] The present invention provides a compound having a structure of Formula I or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope-labeled substance thereof:
[0055]
[0056] in,
[0057] When n is 0,
[0058] X and Y are directly connected, X and Y are CR 4 and CR 5 ;
[0059] R 4 and R 5 are each independently selected from hydrogen, deuterium and C 1-6 alkyl;
[0060] R 1 and R 2 are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl and C 3-8 Cycloalkyl, or, R 1 and R 2 connected to form unsubstituted or one or more R 6 Substituted C 3-8 Cycloalkyl;
[0061] If present, each R 6 are each independently selected from hydrogen, deuterium, hydroxyl, amino, halogen, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl and C 1-6 Alkoxy;
[0062] Or, when n is an integer from 1 to 5,
[0063] XR 1 and YR 2 Each independently selected from carbonyl and CHR 7 ;
[0064] If present, each R 7 are each independently selected from hydrogen, deuterium and C 1-6 alkyl;
[0065] Each Z is independently selected from O, S, CH and N, and when Z is O or S, the R 3 does not exist;
[0066] If present, each R 3 are each independently selected from hydrogen, deuterium and C 1-6 alkyl.
[0067] In a preferred embodiment, when n is 0, X and Y are directly connected, and X and Y are CR 4 and CR 5 , R 4 and R 5 are each independently selected from hydrogen, deuterium and C 1-6 Alkyl, R 1 and R 2 connected to form unsubstituted or one or more R 6 Substituted C 5-8 Cycloalkyl, C 5-8 Cycloalkyl groups include monocyclic, bicyclic, bridged and spirocyclic rings.
[0068] In a preferred embodiment, when n is 0, X and Y are directly connected, and X and Y are CR 4 and CR 5 , R 4 and R 5 are each independently selected from hydrogen, deuterium, methyl and ethyl, R 1 and R 2 connected to form unsubstituted or one or more R 6 Substituted C 5-8 Cycloalkyl, C 5-8 Cycloalkyl is
[0069] In a preferred embodiment, when n is 0, X and Y are directly connected, and X and Y are CR 4 and CR 5 , R 4 and R 5 are each independently selected from hydrogen, deuterium and C 1-6 Alkyl, R 1 and R 2 Connected to form unsubstituted or 1-2 R 6 Substituted C 5-8 Cycloalkyl, if present, each R 6 Each is independently selected from hydrogen, deuterium, hydroxy, amino, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, isopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy and ethoxy.
[0070] In a more preferred embodiment, when n is 0, X and Y are directly connected, and X and Y are CR 4 and CR 5 , R 4 and R 5 are each independently selected from hydrogen and methyl, R 1 and R 2 Connected to form 1-2 R 6 Substituted C 5-8 Cycloalkyl, C 5-8Cycloalkyl is R 6 It is methyl.
[0071] In a preferred embodiment, when n is 0, X and Y are directly connected, and X and Y are CR 4 and CR 5 , R 4 and R 5 are each independently selected from hydrogen, deuterium, methyl and ethyl, R 1 and R 2 are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl and C 3-8 Cycloalkyl.
[0072] In a preferred embodiment, when n is 0, X and Y are directly connected, and X and Y are CR 4 and CR 5 , R 4 and R 5 are each independently selected from hydrogen, deuterium, methyl and ethyl, R 1 and R 2 Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
[0073] In a preferred embodiment, when n is 0, X and Y are directly connected, and X and Y are CR 4 and CR 5 , R 4 and R 5 are each independently selected from hydrogen and methyl, R 1 and R 2 Each is independently selected from hydrogen, fluorine, methyl and cyclopropyl.
[0074] In a preferred embodiment, when n is an integer from 1 to 5, XR 1 and YR 2 All are carbonyl groups.
[0075] In a preferred embodiment, when n is an integer from 1 to 5, each Z is independently selected from CH and N, and each R 3 Each is independently selected from hydrogen, deuterium, methyl, ethyl, n-propyl and isopropyl.
[0076] In a preferred embodiment, n is 3, XR 1 and YR 2 are carbonyl groups, each ZR 3 Each is independently selected from methylene (-CH2-) and N-methyl secondary amino (-N(CH3)-), or n is 1, ZR 3 For methylene.
[0077] In a preferred embodiment, The fragment is Where Z 1 is O, S or N; when Z 1 When it is O or S, the R connected to it 3 does not exist, the rest of R 3 are each independently selected from hydrogen, deuterium, methyl and ethyl; when Z 1 When N, each R 3 Each is independently selected from hydrogen, deuterium, methyl and ethyl.
[0078] In a preferred embodiment, when n is 0,
[0079] X and Y are directly connected, X and Y are CR 4 and CR 5 ,
[0080] R 4 and R 5 are each independently selected from hydrogen, deuterium, methyl and ethyl, preferably hydrogen and methyl;
[0081] R 1 and R 2 are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl and C 3-8 Cycloalkyl, preferably methyl, or, R 1 and R 2 connected to form unsubstituted or substituted with one or more, preferably 1-2 R 6 Substituted C 5-8 Cycloalkyl, C 5-8 Cycloalkyl is Best
[0082] If present, each R 6 Each is independently selected from hydrogen, deuterium, methyl and ethyl, preferably methyl;
[0083] Or, when n is 3,
[0084] XR 1 and YR 2 All are carbonyl groups;
[0085] Each ZR 3 Each is independently selected from methylene and N-methyl secondary amino.
[0086] The present invention also provides a compound or a pharmaceutically acceptable salt, ester, isomer, solvate, prodrug or isotope-labeled substance thereof, wherein the compound is any one of the following:
[0087]
[0088] The present invention also provides a pharmaceutical composition comprising any of the above compounds or pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotope-labeled substances thereof.
[0089] The present invention also provides the use of any of the above compounds or their pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotope labels, or the above pharmaceutical compositions, in the preparation of drugs for preventing and / or treating diseases at least partially mediated by elastase, preferably in the preparation of drugs for preventing and / or treating chronic obstructive pulmonary disease.
[0090] The present invention also provides any of the above-mentioned compounds or their pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotope labels, or the above-mentioned pharmaceutical compositions, which are used as drugs for preventing and / or treating diseases at least partially mediated by elastase, preferably as drugs for preventing and / or treating chronic obstructive pulmonary disease.
[0091] The present invention also provides a method for preventing and / or treating a disease at least partially mediated by elastase, comprising the following steps: administering a therapeutically effective amount of any of the above compounds or their pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotope labels, or the above pharmaceutical composition to a patient in need thereof.
[0092] The following describes a typical synthesis route of the compound represented by general formula I to further describe the technical solution of the present invention, which can be seen in combination with the reaction route shown below:
[0093] Compound 1 and 2 undergo condensation reaction to obtain product 3;
[0094] Product 3 is hydrolyzed with alkali to obtain product 4;
[0095] The product 4 and compound 5 are subjected to condensation reaction to obtain product 6;
[0096] Product 6 is subjected to deprotection reaction to obtain product 7;
[0097] The product 7 and compound 8 undergo condensation reaction to obtain product 9;
[0098] Product 9 is hydrolyzed to obtain product 10.
[0099]
[0100] Wherein n is an integer from 1 to 3.
[0101] As a variation of the above typical reaction route, another reaction route is shown below:
[0102] Compound 10 was deprotected to obtain product 11;
[0103] Product 11 reacts with compound 12 to obtain product 13.
[0104]
[0105] Where n is an integer from 1 to 3, XR 1 , YR 2 and ZR 3 The definition of is as above.
[0106] The present invention is further described in the following examples; however, these examples should not be construed as limiting the scope of the present invention.
[0107] The abbreviations used in the present invention are as follows:
[0108] ACN: Acetonitrile
[0109] CDCl3: deuterated chloroform
[0110] CDI: N,N'-Carbonyldiimidazole
[0111] CD3OD: deuterated methanol
[0112] DIPEA: N,N'-diisopropylethylamine
[0113] DCM: dichloromethane
[0114] DMSO: dimethyl sulfoxide
[0115] DMSO-d6: deuterated dimethyl sulfoxide
[0116] EDCI: 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride
[0117] ESI: Electrospray ionization source
[0118] HCOOH: Formic acid
[0119] 1 H-NMR: Nuclear Magnetic Resonance
[0120] HPLC: High Performance Liquid Chromatography
[0121] HOBt: 1-Hydroxybenzotriazole
[0122] Hz:Hertz
[0123] H2O: water
[0124] LC-MS: Liquid chromatography-mass spectrometry
[0125] LiOH: lithium hydroxide
[0126] MHz: Megahertz
[0127] MS: Mass spectrometry
[0128] NMR: Nuclear Magnetic Resonance
[0129] Petroleum ether: Petroleum ether
[0130] TEA: triethylamine
[0131] TFA: trifluoroacetic acid
[0132] THF: Tetrahydrofuran
[0133] The following describes the general test conditions in the embodiments of the present invention:
[0134] First, the reactions in the examples are generally carried out under nitrogen protection.
[0135] Furthermore, the intermediates and final products are separated and purified by chromatographic columns, preparative chromatographic plates and ICSO rapid preparative chromatographic systems.
[0136] Furthermore, the LC-MS liquid chromatography-mass spectrometry instrument uses Waters ACQUITY Arc equipped with QDaDetector. The mass spectrometry (MS) uses an ESI source and only indicates the molecular weight M of the parent molecule, usually reporting [M+H] + The injection volume was determined by the sample concentration; the flow rate was 0.8 mL / min; the HPLC peak was recorded and read at UV-Vis wavelengths of 220 nm and 254 nm. The mobile phases were 0.01% (w / w) formic acid in ultrapure water (mobile phase A) and 0.01% formic acid in acetonitrile (mobile phase B). The gradient elution conditions are shown in Tables 1 and 2 below:
[0137] Table 1: Gradient elution conditions 1
[0138] Time (min) <![CDATA[A(H2O,0.01%HCOOH)]]> <![CDATA[B(CH3CN,0.01%HCOOH)]]> 0.0-0.3 95-85 5-15 0.3-3.2 85-20 15-80 3.2-3.8 20-5 80-95 3.8-3.81 5-95 95-5 3.81-4.0 95 5
[0139] Table 2: Gradient elution conditions 2
[0140] Time (min) <![CDATA[A(H2O,0.01%HCOOH)]]> <![CDATA[B(CH3CN,0.01%HCOOH) <!-- 9 -->]]> 0.00-5.90 95-5 5-95 5.90-5.91 5-95 95-5 5.91-6.00 95 5
[0141] Further, NMR spectra were obtained using a Varian 400 MHz nuclear magnetic resonance spectrometer, often using CDCl3 and DMSO-d6 as solvents, and chemical shifts were reported in ppm. The descriptions of the various peaks are as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublets). Coupling constants are expressed in Hz.
[0142] Example 1: N-(4-(((S)-3-methyl-1-((S)-2-(((R)-2-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborolan-2-yl)propyl)carbamoyl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamoyl)benzoyl)glycine
[0143] Step 1a: Preparation of N-(N-tert-butyloxycarbonyl-L-valyl)-L-proline methyl ester
[0144]
[0145] Under nitrogen protection, 55.0 g of N-tert-butyloxycarbonyl-L-valine, 46.1 g of L-proline methyl ester hydrochloride, 59.5 g of N,N-diisopropylethylamine and 43.1 g of N,N'-carbonyldiimidazole were dissolved in 200 mL of dichloromethane and stirred at room temperature for 6 hours. HPLC monitoring showed that the reaction was complete. The reaction solution was washed with sodium bicarbonate solution, dilute hydrochloric acid and water respectively. The solvent was removed by concentration under reduced pressure to obtain a light yellow oily intermediate N-(N-tert-butyloxycarbonyl-L-valyl)-L-proline methyl ester (72.0 g).
[0146] Step 1b: Preparation of N-(N-tert-butyloxycarbonyl-L-valyl)-L-proline
[0147]
[0148] Under nitrogen protection, 72.0 g of intermediate N-(N-tert-butyloxycarbonyl-L-valyl)-L-proline methyl ester and 18.4 g of lithium hydroxide were dissolved in 360 mL of tetrahydrofuran and 120 mL of water and stirred at room temperature for 3 hours. HPLC monitoring reaction was complete, 350 mL of 2 wt% sodium hydroxide solution was added to the reaction solution, and the reaction solution was washed with ethyl acetate. The aqueous phase was adjusted to pH 3-4 with hydrochloric acid, and then extracted with ethyl acetate. The organic phases were combined, dried under reduced pressure, 10 mL of ethyl acetate and 400 mL of normal heptane were added to the crude product, stirred at room temperature for 5 hours, filtered and rinsed with 50 mL of normal heptane, and dried under reduced pressure to obtain a white solid intermediate N-(N-tert-butyloxycarbonyl-L-valyl)-L-proline (59.6 g).
[0149] Step 1c: Preparation of tert-butyl ((S)-3-methyl-1((S)-2-(((R)-2-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborolan-2-yl)propyl)carbamoyl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamate
[0150]
[0151] Under nitrogen protection, the intermediate N-(N-tert-butyloxycarbonyl-L-valyl)-L-proline 15.0g, (R)-2-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methylbenzo[d][1,3,2]dioxaborolan-2-yl)propyl-1-amine 17.8g, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 11.9g, 1-hydroxybenzotriazole 8.4g were dissolved in 300mL dichloromethane, N,N-diisopropylethylamine 24.7g was slowly added dropwise at room temperature, the temperature was raised to reflux and stirring was continued for 6 hours. The reaction was monitored by HPLC to be complete. The reaction solution was washed with sodium bicarbonate solution, dilute hydrochloric acid and water. The solvent was removed by concentration under reduced pressure to give the intermediate ((S)-3-methyl-1((S)-2-(((R)-2-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborolan-2-yl)propyl)carbamoyl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamic acid tert-butyl ester (27.04 g) as a light yellow oil.
[0152] Step 1d: Preparation of (S)-1-(L-valyl)-N-((R)-2-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborolan-2-yl)propyl)pyrrolidine-2-carboxamide
[0153]
[0154] Under nitrogen protection, 34.62 g of the intermediate tert-butyl ((S)-3-methyl-1((S)-2-(((R)-2-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborolan-2-yl)propyl)carbamoyl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamate was dissolved in 300 mL of dichloromethane, the temperature was lowered to 0°C, 60 mL of trifluoroacetic acid was slowly added, and stirring was continued for 6 hours. The reaction was completed by HPLC monitoring, and the solvent was removed by concentration under reduced pressure. Then 200 mL of dichloromethane was added, and the pH was adjusted to 9 with sodium bicarbonate solution. The mixture was allowed to stand for stratification, and the aqueous phase was extracted with dichloromethane. The organic phases were combined, washed with water, and concentrated under reduced pressure to remove the solvent to obtain a light yellow oily intermediate (S)-1-(L-valyl)-N-((R)-2-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborolan-2-yl)propyl)pyrrolidine-2-carboxamide (30.9 g).
[0155] Step 1e: Preparation of N-(4-(((S)-3-methyl-1-((S)-2-(((R)-2-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborolan-2-yl)propyl)carbamoyl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamoyl)benzoyl)glycine methyl ester
[0156]
[0157] Under nitrogen protection, the intermediate (S)-1-(L-valyl)-N-((R)-2-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methylbenzo[d][1,3,2]dioxaborolan-2-yl)propyl)pyrrolidine-2-carboxamide 30.9 g and 4-((2-methoxy-2-oxoethyl)carbamoyl)benzoic acid 18.0 g were dissolved in 300 mL of dichloromethane, and 31.4 g of triethylamine was slowly added dropwise at room temperature, and then 15.8 g of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 11.1 g of 1-hydroxybenzotriazole were added, and the temperature was raised to reflux and stirring was continued for 6 hours. HPLC monitoring showed that the reaction was complete. The reaction solution was washed with sodium bicarbonate solution, dilute hydrochloric acid and water in sequence. The solvent was removed by concentration under reduced pressure. The residue was purified by column chromatography to give N-(4-(((S)-3-methyl-1-((S)-2-(((R)-2-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborolan-2-yl)propyl)carbamoyl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamoyl)benzoyl)glycine methyl ester (21.1 g) as a white solid.
[0158] Step 1f: Preparation of N-(4-(((S)-3-methyl-1-((S)-2-(((R)-2-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborolan-2-yl)propyl)carbamoyl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamoyl)benzoyl)glycine
[0159]
[0160] Under nitrogen protection, 2.44 g of the intermediate N-(4-(((S)-3-methyl-1-((S)-2-(((R)-2-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborolan-2-yl)propyl)carbamoyl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamoyl)benzoyl)glycine methyl ester and 0.31 g of lithium hydroxide monohydrate were dissolved in 30 mL of tetrahydrofuran and 10 mL of water, and stirred at room temperature for 2 hours. HPLC monitoring showed that the reaction was complete. The reaction solution was concentrated, and then 15 mL of water was added to the concentrated solution, and the pH of the system was adjusted to 4 with hydrochloric acid. The solution was extracted 3 times with 100 mL of dichloromethane, and the organic phases were combined and concentrated to obtain a white solid crude product. The crude product was added with 2 mL of ethyl acetate and 10 mL of n-heptane, stirred at room temperature for 5 hours, filtered, and the filter cake was rinsed with 5 mL of n-heptane, and dried under reduced pressure to give a white solid N-(4-(((S)-3-methyl-1-((S)-2-(((R)-2-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborolan-2-yl)propyl)carbamoyl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamoyl)benzoyl)glycine (2.27 g), yield 95.0%. 1 H-NMR(CD3OD,400MHz)δ7.89-7.98(m,4H),4.57-4.66(m,2H),4.15-4.21(m,1H), 4.02-4.11(m,3H),3.75-3.83(m,1H),2.49(d,J=6.78Hz,1H),2.02-2.36(m,7H),1 .95 (t, J = 5.40 Hz, 1H), 1.77-1.88 (m, 3H), 1.50 (d, J = 10.29 Hz, 1H), 1.34 (s, 3H), 1.28 (s, 3H), 1.08 (dd, J = 11.04, 6.53 Hz, 6H), 0.95-1.02 (m, 7H), 0.85-0.89 (m, 3H). MS measured value (ESI + )[(M+H) + ]:653.
[0161] Example 2: N-(4-(((S)-3-methyl-1-(S)-2-(((R)-2-methyl-1-(6-methyl-4,8-dioxo-1,3,6,2-dioxazaborolan-2-yl)propyl)carbamoyl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamoyl)benzoyl)glycine
[0162]
[0163] Step 2a: Preparation of N-(4-(((S)-1-((S)-2-(((R)-1-dihydroxyboronyl-2-methylpropyl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamoyl)benzoyl)glycine
[0164]
[0165] Under nitrogen protection, 7.4 g of the intermediate N-(4-(((S)-3-methyl-1-((S)-2-(((R)-2-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborolan-2-yl)propyl)carbamoyl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamoyl)benzoyl)glycine and 2.4 g of 4-trifluoromethylphenylboronic acid were dissolved in 100 mL of acetonitrile and 250 mL of petroleum ether, and then 10 mL of concentrated hydrochloric acid was added. The mixture was stirred for 4 hours from room temperature to 60°C, and the mixture was allowed to stand for stratification. The upper petroleum ether layer was separated, and 250 mL of fresh petroleum ether was added and the mixture was stirred for 4 hours at 60°C. The reaction was monitored to be complete by HPLC. The mixture was allowed to stand for stratification, and the acetonitrile layer was washed with petroleum ether. The solvent was removed by concentration under reduced pressure, and 50 mL of tetrahydrofuran and 300 mL of ethyl acetate were added to the crude product and stirred at room temperature for 6 hours. The mixture was filtered and washed with 10 mL of ethyl acetate. The mixture was dried under reduced pressure to obtain a white solid N-(4-(((S)-1-((S)-2-(((R)-1-dihydroxyboryl-2-methylpropyl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamoyl)benzoyl)glycine (2.75 g) with a yield of 50.8% and a purity of 99.0%.
[0166] Step 2b: Preparation of N-(4-(((S)-3-methyl-1-(S)-2-(((R)-2-methyl-1-(6-methyl-4,8-dioxo-1,3,6,2-dioxazaborolan-2-yl)propyl)carbamoyl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamoyl)benzoyl)glycine
[0167]
[0168] Under nitrogen protection, 300 mg of N-(4-(((S)-1-((S)-2-(((R)-1-dihydroxyboronyl-2-methylpropyl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamoyl)benzoyl)glycine and 102 mg of N-methyliminodiacetic acid were dissolved in 2 mL of dimethyl sulfoxide, then the temperature was raised to 120° C. and stirring was continued for 10 hours. The reaction was completed after monitoring by TLC. The reaction solution was purified by reverse phase column (gradient: 0.01% formic acid acetonitrile: 0.01% formic acid water, 0% to 20%) and lyophilized to give a white solid N-(4-(((S)-3-methyl-1-(S)-2-(((R)-2-methyl-1-(6-methyl-4,8-dioxo-1,3,6,2-dioxazaborolan-2-yl)propyl)carbamoyl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamoyl)benzoyl)glycine (70 mg) in a yield of 19%. 1 H-NMR(400MHz,CD3OD)δ7.94(s,4H),4.65-4.61(m,1H),4.53-4.49(m,1H),4.14-4.01(m,6H),3.84(s,1H),3.78-3.72(m,1H),3.5 8(dd,J=4.0Hz,12.0Hz,1H),2.92(s,3H),2.28-2.16(m,2H),2.10-1.99(m,4H),1.12-1.07(m,6H),0.93(dd,J=4.0Hz,8.0Hz,6H). MS actual measured value (ESI + )[(M+H) + ]:630.
[0169] Example 3: N-(4-(((S)-3-methyl-1-((S)-2-(((R)-2-methyl-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propyl)carbamoyl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamoyl)benzoyl)glycine
[0170]
[0171] Under nitrogen protection, 100 mg of N-(4-(((S)-1((S)-2-(((R)-1-dihydroxyboron-2-methylpropyl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamoyl)benzoyl)glycine and 68 mg of pinacol were dissolved in 0.5 mL of dimethyl sulfoxide, and then the temperature was raised to 120° C. and stirring was continued for 6 hours. The reaction was completed after monitoring by LC-MS. After the reaction solution was freeze-dried, the solid was dissolved in ethyl acetate, purified using a preparative plate, and freeze-dried to give a white solid N-(4-(((S)-3-methyl-1-((S)-2-(((R)-2-methyl-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propyl)carbamoyl)pyrrolidin-1-yl)-1-oxobutan-2-yl)carbamoyl)benzoyl)glycine (45 mg), yield 39%. 1 H-NMR (400MHz, CD3OD) δ7.97-7.90 (m, 4H), 4.67-4.58 (m, 2H), 4.08 (br.s., 4H), 3.79 (d, J = 6.44 Hz, 2H), 2.41 (d, J = 6.19 Hz, 1H), 2.15-2.36 (m, 4H), 2.01-2.12 (m, 2H), 1.84 (td, J = 13.21, 6.57 Hz, 2H), 1.14-1.25 (m, 12H), 1.10 (dd, J = 15.21, 6.70 Hz, 6H), 1.01 (d, J = 6.70 Hz, 2H), 0.91-0.98 (m, 4H). MS measured value (ESI + )[(M+H) + ]:601.
[0172] Stability test
[0173] According to the literature reports, two simulated lung fluids, Gamble's buffer and ALF buffer, were prepared (Marques M.RC, Loebenberg R., Almukainzi M., Simulated Biological Fluids with Possible Application in Dissolution Testing, Dissolution Technologies, 2011, 18 (3): 15-28) to test the stability of the prodrug in the simulated lung fluid. In addition, according to the needs of animal experimental preparations and sample analysis, three different solvents were prepared: animal experimental solvent (water with 5% ethanol), anhydrous ethanol and acetonitrile, which were used to test the stability of the preparations before animal administration and the stability of the collected samples during the analysis process. Take 2 mg of the compounds of Examples 1 and 2 respectively, dissolve them in 1 ml of the filtered buffer or solvent, observe whether there are undissolved particles after vortexing, then filter the suspension or solution to remove the undissolved compounds, and immediately take 100 μl as the sample at the start time of the stability test, and analyze the ratio of the prodrug and the hydrolysis product (i.e., compound 52 in WO 2018 / 175173 A1, used as a control) by HPLC. After that, the samples in the two simulated lung fluids were placed on a 37°C fixed orbital shaker and shaken at 200 rpm, and samples were taken at 0.5 hours, 1 hour, 2 hours, 4 hours, and 20 hours, and the ratio of the prodrug to the hydrolysis product was immediately tested by HPLC. For samples dissolved in three solvents, they were left at room temperature, and samples were taken at 1 hour, 3 hours, 18 hours, etc., and the ratio of the prodrug to the hydrolysis product was immediately detected.
[0174] Test results:
[0175] The compounds of Examples 1 and 2 showed distinct hydrolysis curves and characteristics. Figure 1 As shown in the figure, after the compound of Example 1 was dissolved in two simulated lung fluids, namely, the neutral Gamble's buffer (pH 7.4) and the acidic ALF buffer (pH 4.5), the hydrolysis rate reached 25% and 40% respectively within half an hour, and this ratio was maintained for the next 20 hours, i.e., a stable equilibrium state was reached. Figure 2 As shown, the hydrolysis rate of the compound of Example 2 is linear, and the hydrolysis is faster in the neutral Gamble's buffer (pH 7.4), and is close to 50% hydrolyzed in 2.5 hours, while the hydrolysis is slightly slower in the acidic ALF buffer (pH 4.5), and is about 50% hydrolyzed in about 15 hours. Figure 3As shown, the compound of Example 1 is hardly hydrolyzed in acetonitrile and anhydrous ethanol; in the solvent, the compound of Example 1 is hydrolyzed by about 18% in 3 hours, and then the hydrolysis rate slows down, and is hydrolyzed by about 20% in 18 hours. Figure 4 As shown, the hydrolysis rate test of the compound of Example 2 in three solvents also showed a linear and stable hydrolysis rate, wherein no hydrolysis was found in acetonitrile, about 0.5% of the compound was hydrolyzed per hour in anhydrous ethanol, and about 1% was hydrolyzed per hour in the solvent.
[0176] In vivo pharmacokinetic studies
[0177] The pharmacokinetics of the final prodrug compound of Example 1 and the control (Compound 52 in WO 2018 / 175173 A1) in mice were investigated:
[0178] After an adaptation period, 7-9 week old male C57BL / 6 mice were randomly divided into two groups: an elastase inhibitor control group and an Example 1 group. The dosing details are shown in Table 3.
[0179] Table 3: In vivo pharmacokinetic experimental design in mice
[0180] Grouping Compound Number of animals Dosage dose Group 1 Control 4 Intratracheal administration 2mg / kg Group 2 Example 1 12 Intratracheal administration 2mg / kg
[0181] Results of pharmacokinetic studies in mice:
[0182] In the pharmacokinetic experimental results of mice, the drug concentration of the control in the lung was 153 ng / g after 6 hours and was completely cleared after 12 hours. Figure 5 As shown. Example 1, which is a prodrug of the control substance, is quickly converted into the control substance in the mouse body. Figure 6 As shown, at 6 hours and 12 hours, the concentration of prodrug Example 1 in the lungs was 1070ng / g and 120ng / g, respectively, and the concentration of its hydrolyzate (control) with inhibitory activity in the lungs was also 931ng / g and 264ng / g at 6 hours and 12 hours. The results show that compared with the direct administration of the control itself, prodrug Example 1 greatly increases the concentration and residence time of the control in the lungs. The significant improvement of Example 1 compound in terms of in vivo PK relative to the control.
Claims
1. A compound having a structure of formula I or a pharmaceutically acceptable salt thereof: in, When n is 0, X and Y are directly connected, X and Y are CR 4 and CR 5 ; R 4 and R 5 are each independently selected from hydrogen, deuterium and C 1-6 alkyl; R 1 and R 2 Each independently selected from C 1-6 Alkyl, or R 1 and R 2 connected to form unsubstituted or one or more R 6 Substituted C 3-8 Cycloalkyl; If present, each R 6 are each independently selected from hydrogen, deuterium, hydroxyl, amino, halogen, C 1-6 Alkyl, halogen substituted C 1-6 Alkyl and C 1-6 Alkoxy; Or, when n is an integer from 1 to 5, XR 1 and YR 2 Each independently selected from carbonyl and CHR 7 ; If present, each R 7 are each independently selected from hydrogen, deuterium and C 1-6 alkyl; Each Z is independently selected from O, S, CH and N, and when Z is O or S, the R 3 does not exist; If present, each R 3 are each independently selected from hydrogen, deuterium and C 1-6 alkyl.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that When n is 0, X and Y are directly connected, X and Y are CR 4 and CR 5 , R 4 and R 5 are each independently selected from hydrogen, deuterium and C 1-6 Alkyl, R 1 and R 2 connected to form unsubstituted or one or more R 6 Substituted C 5-8 Cycloalkyl, C 5-8 Cycloalkyl groups include monocyclic, bicyclic, bridged and spirocyclic rings.
3. The compound according to claim 2 or a pharmaceutically acceptable salt thereof, characterized in that: When n is 0, X and Y are directly connected, X and Y are CR 4 and CR 5 , R 4 and R 5 are each independently selected from hydrogen, deuterium, methyl and ethyl, R 1 and R 2 connected to form unsubstituted or one or more R 6 Substituted C 5-8 Cycloalkyl, C 5-8 Cycloalkyl is 4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that: When n is 0, X and Y are directly connected, X and Y are CR 4 and CR 5 , R 4 and R 5 are each independently selected from hydrogen, deuterium and C 1-6 Alkyl, R 1 and R 2 Connected to form unsubstituted or 1-2 R 6 Substituted C 5-8 Cycloalkyl, if present, each R 6 Each is independently selected from hydrogen, deuterium, hydroxy, amino, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, isopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy and ethoxy.
5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that: When n is an integer from 1 to 5, XR 1 and YR 2 All are carbonyl groups.
6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that: When n is an integer of 1-5, each Z is independently selected from CH and N, and each R 3 Each is independently selected from hydrogen, deuterium, methyl, ethyl, n-propyl and isopropyl.
7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that: n is 3, XR 1 and YR 2 are carbonyl groups, each ZR 3 Each independently selected from -CH2- and -N(CH3)-, or, n is 1, ZR 3 For methylene.
8. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein The fragment is Where Z 1 is O, S or N; when Z 1 When it is O or S, the R connected to it 3 does not exist, the rest of R 3 are each independently selected from hydrogen, deuterium, methyl and ethyl; when Z 1 When N, each R 3 Each is independently selected from hydrogen, deuterium, methyl and ethyl.
9. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein When n is 0, X and Y are directly connected, X and Y are CR 4 and CR 5 , R 4 and R 5 are each independently selected from hydrogen, deuterium, methyl and ethyl; R 1 and R 2 Each independently selected from C 1-6 Alkyl, or R 1 and R 2 connected to form unsubstituted or one or more R 6 Substituted C 5-8 Cycloalkyl, C 5-8 Cycloalkyl is If present, each R 6 are each independently selected from hydrogen, deuterium, methyl and ethyl; Or, when n is 3, XR 1 and YR 2 All are carbonyl groups; Each ZR 3 Each is independently selected from -CH2- and -N(CH3)-.
10. A method for preparing a compound of formula 13 or a pharmaceutically acceptable salt thereof, comprising: The compound represented by Formula 11 or a pharmaceutically acceptable salt thereof reacts with the compound represented by Formula 12 to obtain the compound represented by Formula 13 or a pharmaceutically acceptable salt thereof; in, n is an integer from 1 to 3; XR 1 and YR 2 Each independently selected from carbonyl and CHR 7 ; If present, each R 7 are each independently selected from hydrogen, deuterium and C 1-6 alkyl; Each Z is independently selected from O, S, CH and N, and when Z is O or S, the R 3 does not exist; If present, each R 3 are each independently selected from hydrogen, deuterium and C 1-6 alkyl.
11. A pharmaceutical composition comprising the compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof.
12. Use of the compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 11, in the preparation of a medicament for preventing and / or treating a disease at least partially mediated by elastase.
13. The use according to claim 12, characterized in that The disease mediated at least in part by elastase is chronic obstructive pulmonary disease.
